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transformation later in life. Diagnosis is conﬁrmed by the
MPLgene testing. Allogeneic stem cell transplantation
remains the only curative therapy. Due to its rarity, there are
few published reports with variable conditioning regimens
in the allogeneic setting.
We report two female identical twin siblings with
thrombocytopenia at birth (11,000 and 9,000 respectively)
and subsequent work up for persistent low platelets revealed
heterozygous R102P missense mutation on exon 3 of MPL
gene.Nophenotypic abnormalities noted andFanconi anemia
testing was negative. One of them progressed to aplastic
anemia (bone marrow cellularity< 30%, no clonal abnor-
mality) and received conditioning with Cytoxan 50mg/kg x 4
days, reduced dose of TBI at 200cGY x 1 and Campath 3mg/kg
x 4 days followed by transplant with 10/10 allele matched,
unrelated, CMV + donor bone marrow. Tacrolimus alone was
used for GVHD prophylaxis. Sister received myeloablative
conditioning using once a day Busulfan for 4 days based on
pharmacokinetics, Cytoxan 50mg/kg x 4 days, Campath 5mg/
kg x 3 days followed by a transplant with the same unrelated
bonemarrow donor. Tacrolimus andmini methotrexatewere
given on days +1, +3, +6, + 11. Both sisters tolerated the
transplant with minimal toxicity, durable engraftment, and
no acute or chronic GVHD. The ﬁrst twin is approximately 1.5
years post BMT and the second is past day 100.
Formatched unrelated donor transplant, the conditioning
regimen used may be variable based on patients’ clinical
presentation, bone marrow cellularity and presence of
comorbidities.272
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Background: Iron overload especially in heart and liver
cause serious complications for patients with thalassemia
major (TM) including cardiomyopathy which is the main
cause of death in TM patients. Using non-invasive methods
for follow-up, MRI basedmethods like T2*MRI technique has
been recentlymuchmore considered. This study investigates
the changes in iron overload in TM patients before and after
hematopoietic stem cell transplantation (HSCT) using T2*
MRI technique.
Methods: Patients with TM who were candidate for HSCT
enrolled. Cardiac and hepatic T2* values were measured
three times during the treatment; one before HSCT, one six
months later and the other one 12 months after HSCT. These
values were compared to each other to determine how
degree of iron overload changes during one year follow-up.
Results: Twenty-eight patients including 19 boys and 9 girls
with mean age 7.27years (range: 3.5-13) were included. The
mean SD for cardiac T2* values before and after HSCT (6 and
12 months) were 19.007.13, 18.778.25 and 21.727.80
respectively. These numbers for hepatic T2* values were
5.114.03, 3.832.48 and 3.562.69 respectively. While the
differences between cardiac T2* values during one yearfollow-up after HSCT were not statistically signiﬁcant (P-
value¼0.19), hepatic T2* values have decreased signiﬁcantly
(P-value¼0.001) meaning that although cardiac iron over-
load has not changed dramatically, hepatic iron overload is
getting worse even one year after HSCT.
Conclusion: Using T2* MRI for measuring iron overload in
TM patients shows that despite of receiving chelation
therapy or phlebotomy after HSCT, hepatic iron overload is
still getting worse in TM patients whereas cardiac iron
overload is the same as before transplantation. It seems that
for better understanding of liver iron overload, follow-up
should be continued for years later.273
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Background: Transfer of donor immunity for vaccine
preventable diseases in allo-HSCT is limited, requiring re-
vaccination after HSCT. The CDC 2009 guidelines introduced
changes, including earlier vaccination post-HSCT with
a uniform vaccination strategy irrespective of transplant
variables. The CDC guidelines acknowledge vaccination
response varies, but signiﬁcant knowledge gaps exist
regarding factors affecting immune recovery and response to
vaccination post-HSCT. The objective of this study is to
describe predictors of immune recovery and adequate
response to vaccination 1 year post-HSCT.
Methods: We conducted a retrospective chart review of all
pediatric allo-HSCT patients transplanted between July 1,
2007 through June 30, 2012 who survived >1 year post-
transplant without relapse (N¼27). For evaluation of vaccine
response, 8 patients were excluded (5 with incomplete data/
refused vaccines, 2 with cGVHD, 1 receiving IVIG). Adequate
response to vaccination was deﬁned as a > 4-fold increase in
tetanus titers >1 month after vaccination. Wilcoxon Rank-
Sum Exact test and Kruskall-Wallis tests were used to
analyze CD4, CD8, and CD19 counts with a type 1 error rate
ﬁxed at 0.05. Exact conditional logistic regression was
utilized to analyze adequate vaccination response 1 year
post-HSCT.
Results: Overall, a statistically signiﬁcant increase in median
CD4, CD8, and CD19 counts was seen from 6 to 12 months
post-HSCT (P ¼ <0.0001, 0.005, 0.004). Patients with aGVHD
or cGVHD, however, lacked a signiﬁcant increase in cell
counts. Among graft sources, CBU recipients had the highest
median cell counts. Among preparative regimens, patients
with RIC had the lowest median cell counts. Only 36% of
patients had adequate vaccination response at 1 yr post-
HSCT. For the remaining evaluable patients, 88% required one
and 12% required two additional re-vaccination attempts.
None of the variables tested (graft source, preparative
regimen, disease status, ATG/alemtuzumab, GVHD prophy-
laxis, cell counts, GVHD) were statistically signiﬁcant in
predicting adequate vaccine response.
Conclusions: There was no association between predictors
of immune recovery or transplant variables and vaccination
response in this study. A uniform vaccination strategy is
unlikely to provide protective antibodies formany post-HSCT
patients and should be evaluated in larger studies.
